Hepion chair reports 20M-share HEPA insider buys
Hepion Pharmaceuticals Executive Chairman Vincent S. LoPriore, through entities he controls, reported purchases totaling 20,000,000 HEPA-related securities on August 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Hepion Pharmaceuticals Executive Chairman Vincent S. LoPriore, through entities he controls, reported purchases totaling 20,000,000 HEPA-related securities on August 3, 2026. Gravitas Capital LP and Invictus Capital Advisors Pension Plan bought 10,000,000 warrants with a $0.06 exercise price and 10,000,000 common shares at $0.05 per share, all held as indirect ownership.
Insights
Analyzing...
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants F1 | 8,000,000 | $0.00 | $0.00 |
| Purchase | Warrants F2 | 2,000,000 | $0.00 | $0.00 |
| Purchase | Common Stock F1 | 8,000,000 | $0.05 | $400K |
| Purchase | Common Stock F2 | 2,000,000 | $0.05 | $100K |
Footnotes (2)
- F1. Mr. LoPriore is the Managing Member of Gravitas Capital LP and in such capacity has the right to vote and dispose of the securities held by such entity.
- F2. Mr. LoPriore is the trustee and beneficiary of the Invictus Capital Advisors Pension Plan and in such capacity has the right to vote and dispose of the securities held by such entity.
Key Figures
Key Terms
Warrants financial
indirect ownership financial
exercise price financial
dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Hepion Pharmaceuticals (HEPA) insider Vincent S. LoPriore purchase on August 3, 2026?
How many Hepion Pharmaceuticals (HEPA) warrants did Vincent S. LoPriore acquire and at what exercise price?
What common stock purchases in Hepion Pharmaceuticals (HEPA) did Vincent S. LoPriore report?
Through which entities does Vincent S. LoPriore hold his Hepion Pharmaceuticals (HEPA) positions?
What are Vincent S. LoPriore’s reported indirect common stock holdings in Hepion Pharmaceuticals (HEPA) after these transactions?
When do Vincent S. LoPriore’s newly acquired Hepion Pharmaceuticals (HEPA) warrants expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.